ERBB2 and familial pancreatic carcinoma: It is effective in breast cancer [77] and gastric cancer [78] showing HER2 overexpression, and the basket trial for solid cancers showing HER2 overexpression, including pancreatic cancer and biliary tract cancer, is currently in progress (NCT04482309).